Mr Chris Inglefield co-author of important study
Mr Chris Inglefield was involved in and co-author of a study for Merz Pharmaceuticals on the efficacy and safety of incobotulinumtoxinA in the treatment of Upper Facial Lines.
Treating upper facial lines (UFL), a combination of glabellar frown lines, horizontal forehead lines and lateral periorbital lines, is a common aesthetic practice. However, there is no placebo controlled evidence for the efficacy of botulinum toxin Type A in the treatment of whole regions, such as the upper face. The aim of this study was to provide, for the first time, placebo-controlled evidence of the efficacy and safety of incobotulinumtoxinA for the treatment of moderate-to-severe upper facial lines (UFL), that is, the simultaneous treatment of GFL, HFL, and LPL.
You can read the full report here